Most Recent
A judge has approved a $41.45 million settlement in a pelvic mesh class action against manufacturers Covidien and TFS but has put off deciding on the costs of the firm that ran the case, saying it is “next to useless” when law firms appoint their own costs consultants.
A class action over pelvic mesh products supplied by device makers Covidien and TFS has reached a global resolution with the manufacturers and their insurers which brings the recovery total in settled mesh class action close to $450 million.
A class action on behalf of women injured by alleged defective pelvic mesh will not advise group members the estimated average return from the proceeds of a settlement against defunct device manufacturer TFS’ insurer because it would be "cruel".
Settlement talks in a class action on behalf of women injured by allegedly defective pelvic mesh products have failed after Astora Health took a long-standing $27 million settlement offer off the table.
Settlement talks in three class actions on behalf of women injured by allegedly defective pelvic mesh products have progressed “substantially”, a court has heard.
Settlement talks in a class action brought by Shine Lawyers against Astora Women's Health on behalf of women injured by allegedly defective pelvic mesh products are "well advanced", while mediation in two similar actions is ongoing, a court has heard.
A Sydney law firm that brought a class action against Boston Scientific over allegedly defective pelvic mesh products has agreed to stay its case while a class action by Shine Lawyers moves ahead.
Despite a judge's urging for the parties to arrive at a "pragmatic solution", the lawyers behind competing pelvic mesh class actions against Boston Scientific will duke it out for carriage of the proceedings.
Hoping to avoid a lengthy trial like the 89-day hearing in the pelvic mesh class action against Johnson & Johnson's Ethicon, a judge has suggested splitting up a class action hearing over TFS Manufacturing and IVS pelvic mesh products to focus on the question of the devices' safety and efficacy first.